TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06245122: A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CS23546 in Subjects With Advanced Tumors

Sponsor: Chipscreen Biosciences, Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 156 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06245122 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06245122 Rescue Dossier →